Primary Working Impression and Differential Diagnosis
The primary working impression is inadequately controlled Stage 2 hypertension (200/100 mmHg) due to inappropriate monotherapy with metoprolol, a beta-blocker that is not recommended as first-line treatment and is particularly ineffective in elderly patients. 1
Key Diagnostic Considerations
1. Resistant Hypertension vs. Pseudo-Resistance
This patient does NOT meet criteria for true resistant hypertension because she is on monotherapy rather than the required three optimally-dosed medications including a diuretic. 1 However, the differential must address why BP remains severely elevated:
- Medication non-adherence – The most common cause of apparent treatment resistance; requires direct, non-judgmental questioning about missed doses, cost barriers, and side effects 1, 2
- White coat effect – Confirm BP elevation with home monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) before intensifying therapy 1
- Inappropriate medication choice – Beta-blockers like metoprolol are NOT recommended as first, second, or third-line agents for hypertension in the absence of compelling indications (heart failure, recent MI, angina) 1, 3, 2
2. Secondary Causes of Hypertension
Given the severity and long-standing nature despite treatment, screen for:
- Primary aldosteronism – Check aldosterone/renin ratio; most common secondary cause in resistant hypertension 1, 2
- Obstructive sleep apnea – Ask about snoring, witnessed apnea, excessive daytime sleepiness 1, 2
- Renal artery stenosis – Consider in patients with known atherosclerotic disease or worsening renal function 1, 2
- Chronic kidney disease – Check creatinine clearance; CKD with eGFR <30 ml/min contributes to treatment resistance 1
- Drug-induced hypertension – Review for NSAIDs, decongestants, oral contraceptives, stimulants, excessive alcohol, licorice 1, 2
3. Age-Related Considerations (72 Years Old)
- Isolated systolic hypertension – Common in elderly due to arterial stiffening; systolic 200 mmHg with diastolic 100 mmHg suggests both systolic and diastolic elevation 3
- Frailty assessment – Measure orthostatic BP (seated after 5 minutes, then at 1 and 3 minutes standing) to detect orthostatic hypotension before treatment intensification 3
- Functional status – Use validated frailty tools; moderate-to-severe frailty warrants less aggressive BP targets 3
Critical Next Steps
Immediate Actions
Verify BP measurement technique – Use validated automated upper arm cuff with appropriate cuff size (encircling ≥80% of arm), patient seated with back supported for 5 minutes, arm at heart level, average of ≥2 readings 1
Confirm BP elevation – Obtain home BP readings or 24-hour ambulatory monitoring to exclude white coat hypertension 1
Assess adherence – Directly ask about missed doses, side effects (fatigue, bradycardia, sexual dysfunction with metoprolol), and financial barriers 1, 2
Check orthostatic BP – Measure seated and standing BP to detect orthostatic hypotension, which is more common in elderly patients on beta-blockers 1, 3
Diagnostic Workup
- Basic laboratory tests – Serum creatinine, eGFR, electrolytes (sodium, potassium), urinalysis for protein 1
- ECG – Assess for left ventricular hypertrophy or other end-organ damage 1
- Aldosterone/renin ratio – Screen for primary aldosteronism if BP remains uncontrolled after medication optimization 1, 2
- Sleep study referral – If symptoms of obstructive sleep apnea are present 1, 2
Common Pitfalls to Avoid
Do not continue metoprolol monotherapy – Beta-blockers are inferior to ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics for stroke prevention and overall cardiovascular outcomes in elderly hypertensive patients 1, 3, 2
Do not delay treatment intensification – Stage 2 hypertension (≥160/100 mmHg) requires immediate pharmacologic treatment, ideally with two agents from different classes 1
Do not overlook medication-induced causes – Specifically ask about NSAIDs, decongestants, and other BP-elevating substances 1, 2
Do not assume chronological age alone determines treatment – Base decisions on functional status and frailty rather than age; treatment should continue lifelong even beyond age 85 if tolerated 3